- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04776694
Compassionate Use of Dupilumab
October 27, 2023 updated by: Regeneron Pharmaceuticals
Provide Compassionate Use of Dupilumab
Study Overview
Status
Available
Conditions
Intervention / Treatment
Detailed Description
Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications.
Availability will depend on location.
Study Type
Expanded Access
Expanded Access Type
- Individual Patients
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Requests for compassionate use must be initiated by a treating physician. Physicians should contact
- Phone Number: 844-734-6643
- Email: compassionateuserequests@regeneron.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
N/A
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
February 25, 2021
First Submitted That Met QC Criteria
February 25, 2021
First Posted (Actual)
March 2, 2021
Study Record Updates
Last Update Posted (Actual)
October 31, 2023
Last Update Submitted That Met QC Criteria
October 27, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Skin Diseases
- Respiratory Tract Diseases
- Immune System Diseases
- Autoimmune Diseases
- Hypersensitivity, Immediate
- Hematologic Diseases
- Gastrointestinal Diseases
- Gastroenteritis
- Otorhinolaryngologic Diseases
- Pathological Conditions, Anatomical
- Hypersensitivity
- Esophageal Diseases
- Skin Diseases, Vesiculobullous
- Nose Diseases
- Leukocyte Disorders
- Polyps
- Eosinophilia
- Nasal Polyps
- Pemphigoid, Bullous
- Eosinophilic Esophagitis
- Esophagitis
Other Study ID Numbers
- R668-Dupilumab
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bullous Pemphigoid
-
Mayo ClinicEli Lilly and CompanyCompleted
-
AKARI TherapeuticsCompletedBullous Pemphigoid (BP)Germany, Netherlands
-
University Hospital, RouenNot yet recruiting
-
Peking University First HospitalWest China Hospital; Ruijin Hospital; Second Xiangya Hospital of Central South... and other collaboratorsCompleted
-
Assistance Publique Hopitaux De MarseilleUnknownBullous PemphigoidFrance
-
University Hospital, RouenSociété de Dermatologie FrançaiseUnknownBullous PemphigoidFrance
-
CHU de ReimsCompleted
-
Nihon Pharmaceutical Co., LtdCompleted
-
University of IowaGenentech, Inc.Completed
-
University Hospital, LimogesUnknownBullous PemphigoidFrance
Clinical Trials on Dupilumab
-
Brigham and Women's HospitalRegeneron PharmaceuticalsRecruiting
-
Akron Children's HospitalRegeneron Pharmaceuticals; Ohio State UniversityNot yet recruiting
-
University of MichiganRegeneron PharmaceuticalsRecruiting
-
University of California, San FranciscoRecruiting
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAsthma; EosinophilicSpain
-
Montefiore Medical CenterRegeneron PharmaceuticalsRecruitingChronic Rhinosinusitis With Nasal PolypsUnited States
-
Northwestern UniversityRecruitingSkin DiseasesUnited States
-
Johns Hopkins UniversityDoris Duke Charitable FoundationRecruiting
-
SanofiRegeneron PharmaceuticalsRecruiting